MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202621067632 A) filed by Parul University Parul Institute Of Pharmacy on May 29, 2026, for Glycan Conjugated Ceritinib Loaded Chitosan Nanoparticles Formulation And Its Process Thereof.
Inventors include Dr. Priyanka Ahlawat; Mirva Hirpara; Dr. Asha Patel; Drishti Panjwani; Dr. Shruti Patel; Dr. Rajesh K. S; and Dr. Devanshu J. Patel.
The application for the patent was published on July 10, 2026, under issue no. 28/2026.
Abstract: Glycan conjugated ceritinib loaded chitosan nanoparticles and its process thereof Non-small cell lung cancer is the predominant contributor to cancer-related fatalities globally. The present innovation is focused on the formulation of glycan engineered polymer (chitosan) and developing mannose conjugated chitosan nanoparticles containing the drug Ceritinib for the treatment of lung cancer. Modifying the surface with biologically relevant glycans (such as lactose or mannose) or ligands enhances drug accumulation in the tumour microenvironment, due to the presence of these sugar-based receptors on the outside of tumour cells, and they can help drugs get to cancerous regions more easily and hence promotes drug specificity for tumour cells. Priorly the study begins with high- throughput screening of critical formulation and process parameters for fabrication of mannose conjugated chitosan nanoparticles for encapsulating ceritinib, and its optimization via response surface design methodology. Moving towards the conjugation of mannose with chitosan polymer through reductive amination in the presence of sodium tri-acetoxy-borohydride. This mannose-conjugated chitosan is used in the preparation of Ceritinib-loaded mannose-conjugated chitosan nanoparticles using the ionotropic gelation method. The developed formulation was evaluated for characteristic interpretation via particle size, polydispersity, zeta potential, NMR, FTIR, in vitro release studies that showed a sustain biphasic diffusion with 96 hours sustain order release at tumor relevant media pH 6.5. This delineates a prolonged retention and sets forth motif towards advancement in cancer theragnostic in preclinical studies as a potential approach to reduce the frequent dosing and enhance the prolongation in fatal and asymptomatic disease like lung cancer that could enhance the circulation and retention. Thus, the newly developed formulation could be used for better and efficient management of non-small cell lung cancer.
Disclaimer: Curated by HT Syndication.
